Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review

  • Authors:
    • Daniele Xavier Assad
    • Silvia Taveira Elias
    • Andréia Cristina Melo
    • Carlos Gil Ferreira
    • Graziela De Luca Canto
    • Eliete Neves Silva Guerra
  • View Affiliations

  • Published online on: September 20, 2016     https://doi.org/10.3892/ol.2016.5157
  • Pages: 4107-4116
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present systematic review was to analyze the potential impact of mammalian target of rapamycin (mTOR) inhibitors on the treatment of cervical squamous cell carcinoma (CSCC). A systematic literature search was conducted in PubMed, PMC, Scopus, Cochrane Library, LILACS, Web of Science, Google Scholar and ScienceDirect on January 19, 2015, without time and language restrictions. Studies that evaluated women of any age with CSCC and who received mTOR inhibitors alone or in association with other treatments were considered. Randomized and non‑randomized clinical trials were included, and the Preferred Reporting Items for Systematic Reviews and Meta‑Analyses checklist was followed. Selected studies were methodologically appraised according to the Grades of Recommendation, Assessment, Development and Evaluation method to assess the quality of evidence. Of 642 identified citations, 43 studies were fully reviewed; however, only 3 studies met the inclusion criteria and were used for qualitative analysis. Of these, two studies were phase 1 and one was a phase 2 clinical trial. The studies included were not conclusive with regard to the association between mTOR inhibitor treatment and cervical cancer. The main analysis of secondary endpoints revealed that individuals treated with other drugs in association with mTOR inhibitors achieved partial responses (15.4‑33.3%) or stable disease (17.6‑28%). Treatment with mTOR inhibitors in general was well tolerated in patients with metastatic disease. The predominant toxicities were grade 1 and 2. The phase 1 trials included in this review demonstrated that mTOR inhibitor treatments are feasible and safe. However, the currently available evidence is insufficient to determine the effect of mTOR inhibitors on CSCC, and further investigation in high-quality, randomized clinical trials is required.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Assad DX, Elias ST, Melo AC, Ferreira CG, De Luca Canto G and Guerra EN: Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. Oncol Lett 12: 4107-4116, 2016.
APA
Assad, D.X., Elias, S.T., Melo, A.C., Ferreira, C.G., De Luca Canto, G., & Guerra, E.N. (2016). Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. Oncology Letters, 12, 4107-4116. https://doi.org/10.3892/ol.2016.5157
MLA
Assad, D. X., Elias, S. T., Melo, A. C., Ferreira, C. G., De Luca Canto, G., Guerra, E. N."Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review". Oncology Letters 12.5 (2016): 4107-4116.
Chicago
Assad, D. X., Elias, S. T., Melo, A. C., Ferreira, C. G., De Luca Canto, G., Guerra, E. N."Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review". Oncology Letters 12, no. 5 (2016): 4107-4116. https://doi.org/10.3892/ol.2016.5157